<DOC>
<DOCNO>EP-0615446</DOCNO> 
<TEXT>
<INVENTION-TITLE>
SLOW-RELEASE MEDICAMENT CONTAINING A DIHYDROPYRIDINE DERIVATE AS A NANOSOL AND ITS PREPARATION
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K922	A61K951	A61K3144	A61K4742	A61K910	A61K951	A61K910	A61K4742	A61K922	A61K3144	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K9	A61K9	A61K31	A61K47	A61K9	A61K9	A61K9	A61K47	A61K9	A61K31	</CLASSIFICATIONS-FOURTH>
<APPLICANTS>
<APPLICANT-NAME>
ALFATEC PHARMA GMBH
</APPLICANT-NAME>
<APPLICANT-NAME>
ALFATEC-PHARMA GMBH
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
FREIDENREICH JUERGEN
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHICK URSULA
</INVENTOR-NAME>
<INVENTOR-NAME>
WERRY JUERGEN
</INVENTOR-NAME>
<INVENTOR-NAME>
WUNDERLICH JENS-CHRISTIAN
</INVENTOR-NAME>
<INVENTOR-NAME>
FREIDENREICH, JUERGEN
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHICK, URSULA
</INVENTOR-NAME>
<INVENTOR-NAME>
WERRY, JUERGEN
</INVENTOR-NAME>
<INVENTOR-NAME>
WUNDERLICH, JENS-CHRISTIAN
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Sustained-release medicament, containing a 
pharmacologically active dihydropyridine derivative in 

the form of a pharmaceutically administrable nanosol 
which as excipient essentially contains gelatin, 

fractionated gelatin or a gelatin derivative in addition 
to customary pharmaceutical auxiliaries, the nanosol 


a) having an inner phase of the dihydropyridine derivative 
which has a particle size of 10 - 800 nm and 

possesses a surface charge, 
b) an outer phase of gelatin, fractionated gelatin or 
a gelatin derivative, which is oppositely charged, 

and 
c) an approximately or completely isoionic charge state 
of the inner and outer phase and 
d) being physiologically absorbable. 
Medicament according to Claim 1 and/or 2, 
characterized in that the dihydropyridine derivative is 

present as a solid, resuspendable nanodispersion. 
Medicament according to one of Claims 1 to 3, 
characterized in that the dihydropyridine derivative has 

an average particle size of below 400 nm. 
Medicament according to one of Claims 1 to 3, 
characterized in that the gelatin has a maximum in the 

molecular weight distribution in the range from 10⁴ to 
10⁷ D. 
Medicament according to Claim 4, characterized in 
that the gelatin has a maximum in the molecular weight 

distribution of above 9.5 × 10⁴ D and a peptide content 
of less than 5 per cent by weight. 
Medicament according to one of Claims 1 to 5,  
 

characterized in that the gelatin has a per centage 
weight content of the microgel fraction (
>
 10⁷ D) of 
greater than 15 %. 
Medicament according to one of Claims 1 to 6, 
characterized in that an outer phase of the nanosol which 

additionally contains viscosity-increasing substances in 
a weight ratio of gelatin to synthetic or natural polymer 

such as 10:1 to 1000:1. 
Medicament according to one of Claims 1 to 7, 
characterized in that the sustained-release form is a 

tablet. 
Medicament according to Claim 8, characterized in 
that the sustained-release form is a matrix tablet. 
Medicament according to one of Claims 1 to 9, 
characterized in th
at the dihydropyridine derivative is 
present as a sustained-release matrix based on gelatin in 

the form of a pharmaceutically administrable nanosol. 
Medicament according to one of Claims 1 to 10, 
characterized in that the dihydropyridine derivative is 

present partly as an immediate-effect form in the form of 
a pharmaceutically administrable nanosol. 
Medicament according to one of Claims 9 to 11, 
characterized in that the immediate-effect and sustained-release 

forms are present in a hard gelatin capsule. 
Medicament according to one of Claims 1 to 12, 
characterized in that the outer phase is coloured yellow. 
Process for the preparation of a colloidally 
disperse system of a dihydropyridine derivative, 

characterized in that 

a) a gelatin or its derivative is selected according to 
its isoelectric point (IEP) such that its IEP is 

coordinated with the charge state of the dihydropyridine 
derivative particles such that the 

fractionated gelatin or its derivative leads to 
almost or complete charge neutrality with the undissolved 

dihydropyridine derivative at a certain pH, 
b) the (fractionated) gelatin or its derivative is 
converted into the aqueous sol form,  

 
c) the pH is adjusted as a function of the IEP of the 
gelatin to a value such that the nanoparticles of 

the dihydropyridine derivative formed are almost or 
completely stabilized in a neutrally charged form, 

and 
d) before or after stage c) the dihydropyridine 
derivative is dissolved in the aqueous gelatin sol 

or a solution of the dihydropyridine derivative is 
combined with the aqueous gelatin sol. 
Process according to Claim 14, characterized in 
that in stage d) the dissolved dihydropyridine derivative 

is converted into the colloidally disperse form of nanoparticles 
before combination with the aqueous gelatin sol 

and the dispersion of nanoparticles thus obtained is 
combined with the aqueous gelatin sol. 
Process according to Claim 14 or 15, 
characterized in that 

e1) the dihydropyridine derivative precipitates in the 
form of nanoparticles. 
Process according to Claim 14 or 15, 
characterized in that 

e2) the colloidally disperse solution obtained in stage 
d) is spray-dried or freeze-dried and a stable resuspendable 

nanosol is thus obtained which after redissolution 
in aqueous medium yields a colloidally disperse system in 

nanosol form. 
Process according to Claims 14 to 17, 
characterized in that the dihydropyridine derivative 

dissolved in a water-miscible organic solvent is added in 
stage d). 
Process according to one of Claims 14 to 18, 
characterized in that a gelatin having a yellow intrinsic 

colour is employed or a pharmaceutically suitable yellow 
colourant is added to the gelatin solution. 
Process according to one of Claims 14 to 18, 
characterized in that the water-miscible organic solvents 

are added to the aqueous gelatin sol in stage b) and  
 

in stage d) the dihydropyridine derivative is added to 
this mixture in solid form and thus dissolved. 
Process according to Claim 18 or 20, 
characterized in that the organic solvent is subsequently 

removed again. 
Process according to one of Claims 14 to 16, 
characterized in that the nanoparticle solution is 

subsequently dried. 
Process according to Claim 22, characterized in 
that the solution is spray-dried. 
Process according to Claim 22, characterized in 
that the solution is freeze-dried. 
Process according to one of Claims 14 or 15, 
characterized in that following stage d) a water-miscible 

organic solvent is added to loosen the hydration shell of 
the gelatin molecules. 
Process according to Claim 25, characterized in 
that an alcohol is added. 
Process according to Claim 15, characterized in 
that the colloidal particles are prepared continuously 

with an adjustable particle size. 
Process according to Claim 27, characterized in 
that the particle size is continuously measured. 
Process according to one of Claims 14 to 28, 
characterized in that it is carried out continuously. 
Use of a pharmaceutically administrable nanosol 
of a dihydropyridine derivative which as excipient 

essentially contains gelatin, fractionated gelatin or a 
gelatin derivative in addition to customary pharmaceutical 

auxiliaries, the nanosol 

a) having an inner phase of the dihydropyridine derivative 
which has a particle size of 10 - 800 nm and 

possesses a surface charge, 
b) an outer phase of gelatin, fractionated gelatin or 
a gelatin derivative, which is oppositely charged, 

and 
c) an approximately or completely isoionic charge state 
of the inner and outer phase and 
d) being physiologically absorbable. 
  
 

for the production of a calcium antagonist. 
</CLAIMS>
</TEXT>
</DOC>
